Clinical Trial Results and Treatment Resistance with Lamivudine in Hepatitis B

Lamivudine is an effective first-line therapy for chronic hepatitis B virus (HBV) infection, accomplishing the goals of viral suppression, normalization of alanine aminotransferase (ALT) levels, histological improvement, and seroconversion. In the lamivudine clinical trials, up to 32% of patients positive for hepatitis B e antigen (HBeAg) lost HBeAg after 1 year of treatment, and approximately 18% achieved HBeAg seroconversion. ALT levels greater than five times the upper limit of normal increased the likelihood of HBeAg loss. The rates of seroconversion and resistance both increase with the length of treatment. In HBeAg-negative patients, two thirds showed response after 6 to 12 months of therapy, but this response diminished over time despite continued treatment, largely due to the emergence of resistance. Resistance is present in nearly 70% of patients at 5 years. Resistance reverses prior biochemical, virological, and histological gains and can lead to progressive liver failure. Careful patient selection is important, therefore, to maximize the potential for a treatment response under limited therapy.

Lamivudine - resistance - hepatitis B - clinical trials

REFERENCES

• 1 Dienstag J L, Perrillo R P, Schiff E R et al.. A preliminary trial of lamivudine for chronic hepatitis B infection.  N Engl J Med. 1995;  333 1657-1661
• 2 Dienstag J L, Schiff E R, Wright T L et al.. Lamivudine as initial treatment for chronic hepatitis B virus in the United States.  N Engl J Med. 1999;  341 1256-1263
• 3 Lai C L, Chien R N, Leung N W et al.. A one-year trial of lamivudine for chronic hepatitis B.  N Engl J Med. 1998;  339 61-68
• 4 Hoonkoop P, de Man R A, Niesters H G et al.. Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy.  J Viral Hepat. 1998;  5 307-312
• 5 Lok A SF, McMahon B. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations.  Hepatology. 2004;  39 857-867
• 6 Conjeevaram H S, Lok A SF. Management of chronic hepatitis B.  J Hepatol. 2003;  38 S90-S103
• 7 Lok A S, Heathcote E J, Hoofnagle J H. Management of hepatitis B: 2000-summary of a workshop.  Gastroenterology. 2001;  120 1828-1853
• 8 EASL International Consensus Conference on Hepatitis B . 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version).  J Hepatol. 2003;  38 533-540 , (review)
• 9 Gauthier J, Bourne E J, Lutz M W et al.. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine.  J Infect Dis. 1999;  180 1757-1762
• 10 Dienstag J L, Cianciara J, Karayalcin S et al.. Durability of serologic response after lamivudine treatment of chronic hepatitis B.  Hepatology. 2003;  37 748-755
• 11 Liaw Y-F, Sung J JY, Chow W C et al.. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo-controlled clinical trial.  Hepatology. 2003;  38 262A
• 12 Tassopoulos N C, Volpes R, Pastore G et al.. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.  Hepatology. 1999;  29 889-896
• 13 Perrillo R P, Lai C-L, Liaw Y-F et al.. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.  Hepatology. 2002;  36 186-194
• 14 Jonas M M, Kelley D A, Mizerski J et al.. Clinical trial of lamivudine in children with chronic hepatitis B.  N Engl J Med. 2002;  346 1706-1713
• 15 Schalm S W, Heatcote J, Cianciara J et al.. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B virus infection: a randomised trial.  Gut. 2000;  46 562-568
• 16 Schiff E R, Dienstag J L, Karayalcin S et al.. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.  J Hepatol. 2003;  38 818-826
• 17 Dienstag J L, Goldin R D, Heathcote E J et al.. Histological outcome during long-term lamivudine therapy.  Gastroenterology. 2003;  124 105-117
• 18 Santantonio T, Mazzola M, Iacovazzi T et al.. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine.  J Hepatol. 2000;  32 300-306
• 19 Hadzyiannis S J, Papatheodoridis G V, Dimou E et al.. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.  Hepatology. 2000;  32 847-851
• 20 Di Marco V, Marzano A, Lampertico P et al.. The course of anti-HBe/HBV DNA positive chronic liver disease during long-term lamivudine treatment. Program and Abstracts of the 38th Annual Meeting of the European Association for the Study of the Liver July 3-6, 2003 Geneva, Switzerland; (Abstract 4141)
• 21 Liaw Y F, Leung N WY, Chang T T et al.. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B.  Gastroenterology. 2000;  119 172-180
• 22 Leung N WY, Lai C L, Chang T T et al.. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.  Hepatology. 2001;  33 1527-1532
• 23 Guan R, Lai C L, Liaw Y F et al.. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B.  J Gastroenterol Hepatol. 2001;  16(suppl 1) A60
• 24 Chien R N, Liaw Y F, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B.  Hepatology. 1999;  30 770-774
• 25 Lok A SF, Lai C-L, Leung N et al.. Long-term safety of lamivudine treatment in patients with chronic hepatitis B.  Gastroenterology. 2003;  125 1714-1722